

## DAFTAR PUSTAKA

- Asakura, H. and Ogawa, H. (2021) 'COVID-19-associated coagulopathy and disseminated intravascular coagulation', *International Journal of Hematology*. Springer Singapore, 113(1), pp. 45–57. doi: 10.1007/s12185-020-03029-y.
- Azer, S. A. (2020) 'COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics', *New Microbes and New Infections*. Elsevier Ltd, 37(M), p. 100738. doi: 10.1016/j.nmni.2020.100738.
- Battle, D., Wysocki, J. and Satchell, K. (2020) 'Soluble angiotensin-converting enzyme 2: A potential approach for coronavirus infection therapy?', *Clinical Science*, 134(5), pp. 543–545. doi: 10.1042/CS20200163.
- Bhatia, K., Zimmerman, M. A. and Sullivan, J. C. (2013) 'Sex differences in angiotensin-converting enzyme modulation of ang (1-7) levels in normotensive WKY rats', *American Journal of Hypertension*, 26(5), pp. 591–598. doi: 10.1093/ajh/hps088.
- Biswas, S. *et al.* (2021) 'Blood clots in COVID-19 patients: Simplifying the curious mystery', *Medical Hypotheses*, 146(January).
- Brian, D. A. and Baric, R. S. (2005) 'Coronavirus genome structure and replication', *Current Topics in Microbiology and Immunology*, 287, pp. 1–30. doi: 10.1007/3-540-26765-4\_1.
- Caricchio, R. *et al.* (2021) 'Preliminary predictive criteria for COVID-19 cytokine storm', *Annals of the Rheumatic Diseases*, 80(1), pp. 88–95. doi: 10.1136/annrheumdis-2020-218323.
- Cevik, M. *et al.* (2020) 'Virology, transmission, and pathogenesis of SARS-CoV-2', *The BMJ*, 371, pp. 1–6. doi: 10.1136/bmj.m3862.
- Chamarthi, B. *et al.* (2011) 'Inflammation and Hypertension: The Interplay of Interleukin-6, Dietary Sodium and the Renin-Angiotensin System in Humans Bindu', *American Journal of Hypertension*, 24(10), pp. 1–13. doi: 10.1038/ajh.2011.113.
- Chen, Q. *et al.* (2020) 'Clinical characteristics of 145 patients with corona virus disease 2019 ( COVID - 19 ) in Taizhou , Zhejiang , China', *Infection*. Springer Berlin Heidelberg, 48(4), pp. 543–551. doi: 10.1007/s15010-020-01432-5.
- Cui, J., Li, F. and Shi, Z. L. (2019) 'Origin and evolution of pathogenic coronaviruses', *Nature Reviews Microbiology*. Springer US, 17(3), pp. 181–192. doi: 10.1038/s41579-018-0118-9.
- Donnelly, C. A. *et al.* (2019) 'Worldwide reduction in MERS cases and deaths since 2016', *Emerging Infectious Diseases*, 25(9), pp. 1758–1760. doi: 10.3201/eid2509.190143.

Durand, M., Troyanov, Y. and Laflamme, P. (2010) 'The Journal of Rheumatology Macrophage Activation Syndrome Treated with Anakinra Volume 37 , no . 4 The Journal of Rheumatology is a monthly international serial edited by Duncan A . Gordon featuring research articles on clinical subjects from scientists ', 37(4).

Eljilany, I. and Elzouki, A. N. (2020) 'D-dimer, fibrinogen, and il-6 in covid-19 patients with suspected venous thromboembolism: A narrative review', *Vascular Health and Risk Management*, 16, pp. 455–462. doi: 10.2147/VHRM.S280962.

Fajgenbaum, D. C. and June, C. H. (2020) 'Cytokine Storm', *New England Journal of Medicine*, 383(23), pp. 2255–2273. doi: 10.1056/nejmra2026131.

Gando, S., Levi, M. and Toh, C. H. (2016) 'Disseminated intravascular coagulation', *Nature Reviews Disease Primers*. Macmillan Publishers Limited, 2(Dic), pp. 1–16. doi: 10.1038/nrdp.2016.37.

Giannitsis, E. *et al.* (2017) 'How to use D-dimer in acute cardiovascular care', *European heart journal. Acute cardiovascular care*, 6(1), pp. 69–80. doi: 10.1177/2048872615610870.

Grupp, S. A. *et al.* (2013) 'Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia', *New England Journal of Medicine*, 368(16), pp. 1509–1518. doi: 10.1056/nejmoa1215134.

Guan, W. *et al.* (2020) 'Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis', *European Respiratory Journal*, 55, pp. 1–14. doi: 10.1183/13993003.00547-2020.

Gubernatorova, E. O. *et al.* (2020) 'IL-6: Relevance for immunopathology of SARS-CoV-2', *Cytokine and Growth Factor Reviews*. Elsevier, 53(May 2020), pp. 13–24. doi: 10.1016/j.cytogfr.2020.05.009.

Hermine, O. *et al.* (2021) 'Effect of Tocilizumab vs Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial', *JAMA Internal Medicine*, 181(1), pp. 32–40. doi: 10.1001/jamainternmed.2020.6820.

Horby, P. *et al.* (2021) 'Dexamethasone in Hospitalized Patients with Covid-19', *New England Journal of Medicine*, 384(8), pp. 693–704. doi: 10.1056/nejmoa2021436.

Hottz, E. D. *et al.* (2020) 'Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19', *American Society of Haematology*, 136(11), pp. 1330–1341. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254017/pdf/main.pdf>.

Hu, D. *et al.* (2021) 'Influence of age and gender on the epidemic of COVID-19: Evidence from 177 countries and territories—an exploratory, ecological study', *Wiener Klinische Wochenschrift*, 133(7–8), pp. 321–330.

doi: 10.1007/s00508-021-01816-z.

Huang, C. *et al.* (2020) 'Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China', *The Lancet*, 395(10223), pp. 497–506. doi: 10.1016/S0140-6736(20)30183-5.

Huang, K. J. *et al.* (2005) 'An interferon- $\gamma$ -related cytokine storm in SARS patients', *Journal of Medical Virology*, 75(2), pp. 185–194. doi: 10.1002/jmv.20255.

Imam, Z. *et al.* (2020) 'Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States', pp. 469–476. doi: 10.1111/joim.13119.

Ji, W. *et al.* (2020) 'Analysis clinical features of COVID-19 infection in secondary epidemic area and report potential biomarkers in evaluation', *medRxiv*, pp. 0–5. doi: 10.1101/2020.03.10.20033613.

Joncour, A. Le *et al.* (2020) 'Neutrophil – Platelet and Monocyte – Platelet Aggregates in COVID-19 Patients', pp. 29–31.

Kamal, A. H., Tefferi, A. and Pruthi, R. K. (2007) 'How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults', *Mayo Clinic Proceedings*, 82(7), pp. 864–873. doi: 10.4065/82.7.864.

Kang, S.-J. and Jung, S.-I. (2020) 'COVID-19-ASSOCIATED MORBIDITY AND MORTALITY ACCORDING TO AGE', *Infection and Chemotherapy*, 52(2), pp. 154–164. doi: 10.3947/ic.2020.52.2.154.

Kang, S. *et al.* (2019) 'Targeting Interleukin-6 Signaling in Clinic', *Immunity*. Elsevier Inc., 50(4), pp. 1007–1023. doi: 10.1016/j.immuni.2019.03.026.

Kang, S. J. and Jung, S. I. (2020) 'Age-Related Morbidity and Mortality among Patients with COVID-19', *Infection and Chemotherapy*, 52(2), pp. 154–164. doi: 10.3947/ic.2020.52.2.154.

Khailany, R. A., Safdar, M. and Ozaslan, M. (2020) 'Genomic characterization of a novel SARS-CoV-2', *Gene Reports*. Elsevier, 19(March), p. 100682. doi: 10.1016/j.genrep.2020.100682.

Klein, S. L. (2012) 'Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases', *BioEssays*, 34(12), pp. 1050–1059. doi: 10.1002/bies.201200099.

Klein, S. L. *et al.* (2020) 'Biological sex impacts COVID-19 outcomes', *PLoS Pathogens*, 16(6), pp. 1–5. doi: 10.1371/journal.ppat.1008570.

Klok, F. A. *et al.* (2020) 'Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis', *Thrombosis Research*. Elsevier, 191(xxxx), pp. 148–150. doi: 10.1016/j.thromres.2020.04.041.

Laishram, V. *et al.* (2016) 'Interleukin-6 in obese type II diabetes with hypertension', *International Journal of Research in Medical Sciences*, 4(3), pp. 896–901. doi: 10.18203/2320-6012.ijrms20160539.

Lauder, S. N. *et al.* (2013) 'Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology', *European Journal of Immunology*, 43(10), pp. 2613–2625. doi: 10.1002/eji.201243018.

Lee, D. W. *et al.* (2014) 'Current concepts in the diagnosis and management of cytokine release syndrome', *Blood*, 124(2), pp. 188–195. doi: 10.1182/blood-2014-05-552729.

Lescure, F. X. *et al.* (2020) 'Clinical and virological data of the first cases of COVID-19 in Europe: a case series', *The Lancet Infectious Diseases*, 20(6), pp. 697–706. doi: 10.1016/S1473-3099(20)30200-0.

Levi, M. *et al.* (2003) 'Infection and inflammation and the coagulation system', *Cardiovascular Research*, 60(1), pp. 26–39. doi: 10.1016/S0008-6363(02)00857-X.

Levi, M. *et al.* (2009) 'Guidelines for the diagnosis and management of disseminated intravascular coagulation', *British Journal of Haematology*, 145(1), pp. 24–33. doi: 10.1111/j.1365-2141.2009.07600.x.

Levi, M. *et al.* (2020) 'Coagulation abnormalities and thrombosis in patients with COVID-19', *The Lancet Haematology*, 7(6), pp. e438–e440. doi: 10.1016/S2352-3026(20)30145-9.

Levi, M. and van der Poll, T. (2017) 'Coagulation and sepsis', *Thrombosis Research*. Elsevier B.V., 149, pp. 38–44. doi: 10.1016/j.thromres.2016.11.007.

Levy, J. H. *et al.* (2014) 'Clinical use of the activated partial thromboplastin time and prothrombin time for screening: A review of the literature and current guidelines for testing', *Clinics in Laboratory Medicine*, 34(3), pp. 453–477. doi: 10.1016/j.cll.2014.06.005.

Liu, B. *et al.* (2020) 'Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?', *Elsevier Inc.*, (January). doi: <https://doi.org/10.1016/j.jaut.2020.102452>.

Liu, Y. *et al.* (2020) 'Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study', *Platelets*, 31(4), pp. 490–496. doi: 10.1080/09537104.2020.1754383.

Long, H. *et al.* (2020) 'D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis', *BioMed Research International*, 2020. doi: 10.1155/2020/6159720.

Lucas, C. *et al.* (2020) 'Longitudinal analyses reveal immunological misfiring in severe COVID-19', *Nature*, 584(7821), pp. 463–469. doi: 10.1038/s41586-020-2588-y.

- Marchandot, B. *et al.* (2020) 'COVID-19 related coagulopathy: A distinct entity?', *Journal of Clinical Medicine*, 9(6), pp. 1–17. doi: 10.3390/jcm9061651.
- Mathew, D. *et al.* (2020) 'Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions.', *bioRxiv : the preprint server for biology*, 8511(July), pp. 1–29. doi: 10.1101/2020.05.20.106401.
- Moore, J. B. and June, C. H. (2020) 'Cytokine release syndrome in severe COVID-19', *Science*, 368, pp. 473–4. doi: <https://doi.org/10.1126/science.abb8925>.
- Nile, S. H. *et al.* (2020) 'COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons', *Cytokine and Growth Factor Reviews*, 53, pp. 66–70. doi: 10.1016/j.cytogfr.2020.05.002.
- Ogedegbe, H. O. (2002) 'An overview of hemostasis', *Laboratory Medicine*, 33(12), pp. 948–953. doi: 10.1309/50UQ-GUPF-W6XW-1X7B.
- Poon, L. L. M. *et al.* (2004) 'The aetiology, origins, and diagnosis of severe acute respiratory syndrome', *Lancet Infectious Diseases*, 4(11), pp. 663–671. doi: 10.1016/S1473-3099(04)01172-7.
- Qian, J. *et al.* (2020) 'Age-dependent Gender Differences in COVID-19 in Mainland China: Comparative Study', *Clinical Infectious Diseases*, 71(9), pp. 2488–2494. doi: <https://doi.org/10.1093/cid/ciaa683>.
- Ragab, D. *et al.* (2020) 'The COVID-19 Cytokine Storm; What We Know So Far', *Frontiers in Immunology*, 11(June), pp. 1–4. doi: 10.3389/fimmu.2020.01446.
- Ranucci, M. *et al.* (2020) 'The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome', *Journal of Thrombosis and Haemostasis*, 18(7), pp. 1747–1751. doi: 10.1111/jth.14854.
- Reaven, G. M., Lithell, H. and Landsberg, L. (1996) 'Hypertension and associated metabolic abnormalities-The role of insulin resistance and the sympathoadrenal system', *The New England Journal of Medicine*, 334(6), pp. 374–381. doi: 10.1056/NEJM199602083340607.
- Repsold, L. and Joubert, A. M. (2021) 'Platelet function, role in thrombosis, inflammation, and consequences in chronic myeloproliferative disorders', *Cells*. MDPI, 10(11). doi: 10.3390/CELLS10113034.
- Rose-John, S. (2012) 'Il-6 trans-signaling via the soluble IL-6 receptor: Importance for the proinflammatory activities of IL-6', *International Journal of Biological Sciences*, 8(9), pp. 1237–1247. doi: 10.7150/ijbs.4989.
- Schurz, H. *et al.* (2019) 'The X chromosome and sex-specific effects in infectious disease susceptibility', *Human genomics*. Human Genomics, 13(1), p. 2. doi: 10.1186/s40246-018-0185-z.
- Sinha, P., Matthay, M. A. and Calfee, C. S. (2020) 'Is a "cytokine Storm"

Relevant to COVID-19?', *JAMA Internal Medicine*, 180(9), pp. 1152–1154. doi: 10.1001/jamainternmed.2020.3313.

Soy, M. *et al.* (2020) 'Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment', *Clinical Rheumatology*, 39(7), pp. 2085–2094. doi: 10.1007/s10067-020-05190-5.

Srivastava, S. *et al.* (2020) 'COVID-19 infection and thrombosis', *Clinica Chimica Acta*, 510(June), pp. 344–346. doi: 10.1016/j.cca.2020.07.046.

Stone, J. H. *et al.* (2020) 'Efficacy of Tocilizumab in Patients Hospitalized with Covid-19', *New England Journal of Medicine*, 383(24), pp. 2333–2344. doi: 10.1056/nejmoa2028836.

Tanaka, T., Narazaki, M. and Kishimoto, T. (2014) 'Il-6 in inflammation, Immunity, And disease', *Cold Spring Harbor Perspectives in Biology*, 6(10). doi: 10.1101/cshperspect.a016295.

Tang, N. *et al.* (2020) 'Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia', *Journal of Thrombosis and Haemostasis*, 18(4), pp. 844–847. doi: 10.1111/jth.14768.

Taylor, J. *et al.* (2001) 'Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation: On behalf of the scientific subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and ', *Thrombosis and Haemostasis*, 86(5), pp. 1327–1330. doi: 10.1055/s-0037-1616068.

Teachey, D. T., Rheingold, S. R. and Maude, S. L. (2016) 'Erratum: Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy (Blood (2013) 121:26 (5154-5157))', *Blood*, 128(10), p. 1441. doi: 10.1182/blood-2016-07-730671.

Tripodi, A. (2011) 'D-dimer testing in laboratory practice', *Clinical Chemistry*, 57(9), pp. 1256–1262. doi: 10.1373/clinchem.2011.166249.

Utrero-Rico, A. *et al.* (2021) 'IL-6–based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts', *Journal of Allergy and Clinical Immunology*, 147(5), pp. 1652–1661.e1. doi: 10.1016/j.jaci.2021.02.021.

Vabret, N. *et al.* (2020) 'Immunology of COVID-19: Current State of the Science', *Immunity*. Cell Press, 52(6), pp. 910–941. doi: 10.1016/J.IMMUNI.2020.05.002.

Del Valle, D. M. *et al.* (2020) 'An inflammatory cytokine signature predicts COVID-19 severity and survival', *Nature Medicine*. Springer US, 26(10), pp. 1636–1643. doi: 10.1038/s41591-020-1051-9.

Wada, H., Matsumoto, T. and Yamashita, Y. (2014) 'Diagnosis and

treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines', *Journal of Intensive Care*, 2(1), pp. 1–8. doi: 10.1186/2052-0492-2-15.

Wakai, A., Gleeson, A. and Winter, D. (2003) 'Role of fibrin D-dimer testing in emergency', *Emergency Medicine Journal*, 20(4), pp. 319–325.

Wen Tan, C. *et al.* (2021) 'Clinical and laboratory features of hypercoagulability in COVID-19 and other respiratory viral infections amongst predominantly younger adults with few comorbidities COVID-19 caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and other', *Nature*, 11, p. 1793. doi: 10.1038/s41598-021-81166-y.

Wiersinga, W. J. *et al.* (2020) 'Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review', *JAMA - Journal of the American Medical Association*, 324(8), pp. 782–793. doi: 10.1001/jama.2020.12839.

Xiang, G. *et al.* (2021) 'The effect of coagulation factors in 2019 novel coronavirus patients: A systematic review and meta-analysis', *Medicine*, 100(7), p. e24537. doi: 10.1097/MD.00000000000024537.

Xu, Z. *et al.* (2020) 'Pathological findings of COVID-19 associated with acute respiratory distress syndrome', *The Lancet Respiratory Medicine*. Elsevier Ltd, 8(4), pp. 420–422. doi: 10.1016/S2213-2600(20)30076-X.

Yanez, N. D. *et al.* (2020) 'COVID-19 mortality risk for older men and women', *BMC Public Health*. BMC Public Health, 20(1), pp. 1–7. doi: 10.1186/s12889-020-09826-8.

Yorike, D., Kurniawan, M. R. and Syafaat, M. (2022) 'Analysis of D-Dimer Level and Prothombin Time (PT) Activated Prothombin Thromboplastin (APTT) on Heparin Administration to COVID-19 Patients', *Indonesian Journal of Medical Laboratory Science and Technology*, 4(1), pp. 91–98. doi: 10.33086/ijmlst.v4i1.2487.

Younes, N. *et al.* (2020) 'Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2', *Viruses*, 12(6), pp. 1–44. doi: 10.3390/v12060582.

Yüce, M., Filiztekin, E. and Özkaya, K. G. (2021) 'COVID-19 diagnosis —A review of current methods', *Biosensors and Bioelectronics*, 172(October 2020). doi: 10.1016/j.bios.2020.112752.

Zeng, F. *et al.* (2020) 'A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex COVID-19 patients, SARS-CoV-2 IgG antibody, sexual discrepancy', *J Med Virol*, 92, pp. 2050–2054. doi: 10.1002/jmv.25989.

Zhou, X. *et al.* (2021) 'Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis', *Thrombosis Research*, 201(January), pp. 23–29. doi:

10.1016/j.thromres.2021.02.010.


Zhu, N. *et al.* (2020) 'A Novel Coronavirus from Patients with Pneumonia in China, 2019', *New England Journal of Medicine*, 382(8), pp. 727–733. doi: 10.1056/nejmoa2001017.

Zhu, Z. *et al.* (2020) 'Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019', *International Journal of Infectious Diseases*. International Society for Infectious Diseases, 95, pp. 332–339. doi: 10.1016/j.ijid.2020.04.041.



# LAMPIRAN

Lampiran 1 Rekomendasi Persetujuan Etik



## REKOMENDASI PERSETUJUAN ETIK

Nomor : 73/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 14 Februari 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22020065	No Sponsor Protokol	
Peneliti Utama	dr. Natalia Widjaya	Sponsor	
Judul Peneliti	Dinamika Interleukin-6 (IL-6) Dan D-dimer Pada Pasien COVID-19 Yang Berakhir Dengan Kematian		
No Versi Protokol	1	Tanggal Versi	11 Februari 2022
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RS Universitas Hasanuddin Dan RS Dr. Wahidin Sudirohusodo		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 14 Februari 2022 sampai 14 Februari 2023	Frekuensi review lanjutan
Ketua KEPK FKUH RSUH dan RSWs	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris KEPK FKUH RSUH dan RSWs	Nama dr. Agussalim Bulharti, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

### Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2 Daftar Subjek Penelitian

No Urut	JK	Umur	Komorbid					
			HPT	DM	Jantung	Paru	Ginjal	Autoimun
1	P	19-60 tahun	-	-	-	-	-	-
2	L	> 60 tahun	√	√	√	-	-	-
3	L	> 61 tahun	-	-	-	-	-	-
4	L	19-60 tahun	-	-	-	√	-	-
5	P	> 60 tahun	-	-	-	-	-	-
6	P	> 60 tahun	-	-	-	-	√	-
7	L	19-60 tahun	-	√	-	-	-	-
8	L	19-60 tahun	-	√	-	-	-	-
9	L	19-60 tahun	-	√	√	-	-	-
10	L	> 60 tahun	√	-	-	-	-	-
11	L	> 60 tahun	-	-	-	-	-	-
12	P	> 60 tahun	√	√	-	-	-	-
13	P	19-60 tahun	√	√	-	-	-	-
14	L	> 60 tahun	-	-	-	-	-	-
15	L	19-60 tahun	-	√	-	-	-	-
16	P	> 60 tahun	√	-	-	-	-	-
17	L	19-60 tahun	-	-	-	-	-	√
18	L	> 60 tahun	-	√	-	-	-	-
19	L	19-60 tahun	-	-	-	-	-	-
20	P	> 60 tahun	-	-	-	-	-	-
21	P	19-60 tahun	-	-	-	-	-	-
22	L	> 60 tahun	√	√	-	-	√	-
23	L	19-60 tahun	√	√	-	-	-	-
24	P	> 60 tahun	√	-	-	-	-	-
25	P	19-60 tahun	√	-	-	-	-	-
26	L	> 60 tahun	√	-	-	-	-	-
27	L	> 60 tahun	√	√	-	-	-	-
28	P	> 60 tahun	√	√	-	-	-	√
29	P	> 60 tahun	-	√	-	-	-	-
30	L	> 60 tahun	-	-	-	-	-	-
31	L	> 60 tahun	√	-	-	-	√	-
32	L	> 60 tahun	√	√	√	-	√	-
33	L	> 60 tahun	√	-	-	-	-	-
34	L	> 60 tahun	-	-	-	-	-	-
35	L	19-60 tahun	-	-	-	-	-	-
36	L	> 60 tahun	√	-	-	-	-	-
37	P	> 60 tahun	-	√	√	-	-	-
38	L	19-60 tahun	-	-	-	-	-	-
39	P	> 60 tahun	-	√	-	-	-	-

No Urut	PT	INR	aPTT	PLT	IL-6	D-dimer	Derajat COVID-19
	10 - 14 detik		22-30 detik	150 - 450 10 <sup>3</sup> /uL	<=7.00 pg/mL	< 0.5 Ug/mL	
1	10.3	0.99	35.1	326	36.77	82.5	Severe
2	17.2	1.74	44.3	206	2897	1.87	Severe
3	16.1	1.62	39.6	113	1840	14.8	Severe
4	14.1	1.4	38.7	158	189.3	10,5	Severe
5	11.0	1.06	27.1	201	332.7	5.64	non-Severe
6				281	36.31	23.0	Severe
7	12.2	1.91	24.1	288	89.42	23.3	Severe
8				100	60.37	1100	Severe
9	20.3	2.05	38.4	304	5000	3.40	Severe
10	10.8	1.04	46	172	5000	5.35	Severe
11	13.4	1.31	29.5	73	714.6	8.19	non-Severe
12				68	10	12.3	Severe
13	10.3	0.99	48.2	204	109	3.63	Severe
14	15.0	1.50	20.3	72	31.24	28.9	Severe
15	13.7	1.35	32.1	332	169.6	37.5	Severe
16	21.5	2.19	28.1	469	47.18	3.79	Severe
17	23	2.34	54.7	94	62.16	6.84	non-Severe
18	10.8	1.04	27.2	222	1538	16.6	Severe
19	10.9	1.05	32.6	252	147.8	1.68	Severe
20	16.6	1.67	28.6	154	83.28	1.96	Severe
21	12.5	1.22	17.9	242	521.9	4.17	Severe
22	11.1	1.07	35.71	206	2218	0.82	Severe
23	18.2	1.85	42.3	116	73.42	10.72	non-Severe
24	11.4	1.1	32.2	243	104.7	1.18	non-Severe
25				264	117	41.2	Severe
26					29.97	4.36	Severe
27	10.4	1.00	29.9	200	168.1	2.34	Severe
28	14.1	1.38	23	211	30.09	10.0	Severe
29	13.4	1.32	28.9	230	2905	34.3	Severe
30	12.0	1.17	27.7	121	90.87	56.30	Severe
31	15.4	1.54	31.4	187	144.6	81.0	Severe
32	15.4	1.52	39.7	20	62.36	19.80	Severe
33	11.3	1.07	26.7	317	41.02	35.2	Severe
34				115	15.99	1120	Severe
35				258	18.78	1.17	Severe
36	32.1	1.2	14.5	342	13.19	2.0	Severe
37	46.1	1.34	15.0	230	787.8	1214.52	Severe
38				260	426.5	58.1	non-Severe
39				225	104.7	1.19	Severe

Lampiran 3 Jenis Kelamin

**Jenis\_Kelamin**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki_laki	25	64.1	64.1	64.1
	Perempuan	14	35.9	35.9	100.0
	Total	39	100.0	100.0	

Lampiran 4 Umur

**Umur**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	< 60 tahun	14	35.9	35.9	35.9
	≥ 60 tahun	25	64.1	64.1	100.0
	Total	39	100.0	100.0	

Lampiran 5 Derajat Klinis Covid-19

**Derajat\_Covid19**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	non Severe	6	15.4	15.4	15.4
	Severe	33	84.6	84.6	100.0
	Total	39	100.0	100.0	

Lampiran 6 Riwayat Komorbid Pada Pasien Covid-19

**Komorbid**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tanpa Komorbid	11	28.2	28.2	28.2
	Dengan Komorbid	28	71.8	71.8	100.0
	Total	39	100.0	100.0	

Lampiran 7 Karakteristik Hasil Pemeriksaan Laboratorium

**Statistics**

		APTT	PT	Trombosit	D_dimer	IL6
N	Valid	30	30	38	39	39
	Missing	9	9	1	0	0
Mean		31.9837	15.6867	207.2632	107.2979	673.5569
Median		30.6500	13.5500	208.5000	10.7200	104.7000
Std. Deviation		9.60096	7.44125	92.94337	304.80143	1274.63409
Minimum		14.50	10.30	20.00	.82	10.00
Maximum		54.70	46.10	469.00	1214.52	5000.00

Lampiran 8 Rerata Median Hasil Pemeriksaan Laboratorium Terhadap Derajat Covid-19

<b>Descriptives</b>				
	Derajat_Covid19		Statistic	Std. Error
APTT	non Severe	Mean	37.1600	5.09192
		Median	32.2000	
		Std. Deviation	11.38587	
		Minimum	27.10	
		Maximum	54.70	
	Severe	Mean	30.9484	1.82294
		Median	29.9000	
		Std. Deviation	9.11468	
		Minimum	14.50	
		Maximum	48.20	
PT	non Severe	Mean	15.4000	2.29085
		Median	13.4000	
		Std. Deviation	5.12250	
		Minimum	11.00	
		Maximum	23.00	
	Severe	Mean	15.7440	1.58132
		Median	13.7000	
		Std. Deviation	7.90659	
		Minimum	10.30	
		Maximum	46.10	
Trombosit	non Severe	Mean	145.4000	32.68425
		Median	116.0000	
		Std. Deviation	73.08420	
		Minimum	73.00	
		Maximum	243.00	
	Severe	Mean	223.1200	19.10928
		Median	211.0000	
		Std. Deviation	95.54638	
		Minimum	20.00	
		Maximum	469.00	

D_dimer	non Severe	Mean	6.5140	1.57831
		Median	6.8400	
		Std. Deviation	3.52920	
		Minimum	1.18	
		Maximum	10.72	
	Severe	Mean	71.6292	47.96951
		Median	14.8000	
		Std. Deviation	239.84753	
		Minimum	.82	
		Maximum	1214.52	
IL6	non Severe	Mean	257.5160	124.49628
		Median	104.7000	
		Std. Deviation	278.38213	
		Minimum	62.16	
		Maximum	714.60	
	Severe	Mean	966.4608	303.38626
		Median	147.8000	
		Std. Deviation	1516.93130	
		Minimum	13.19	
		Maximum	5000.00	

Lampiran 9 Rerata Median Hasil Pemeriksaan Laboratorium Terhadap Riwayat Komorbid Pada Pasien Covid-19

<b>Descriptives</b>				
	Komorbid		Statistic	Std. Error
APTT	Tanpa Komorbid	Mean	28.7111	2.25582
		Median	28.6000	
		Std. Deviation	6.76747	
		Minimum	17.90	
		Maximum	39.60	
	Dengan Komorbid	Mean	33.3862	2.27255
		Median	32.1000	
		Std. Deviation	10.41415	
		Minimum	14.50	
		Maximum	54.70	

PT	Tanpa Komorbid	Mean	13.0889	.77825
		Median	12.5000	
		Std. Deviation	2.33476	
		Minimum	10.30	
		Maximum	16.60	
	Dengan Komorbid	Mean	16.8000	1.87427
		Median	14.1000	
		Std. Deviation	8.58900	
		Minimum	10.30	
		Maximum	46.10	
Trombosit	Tanpa Komorbid	Mean	172.6667	29.35889
		Median	154.0000	
		Std. Deviation	88.07667	
		Minimum	72.00	
		Maximum	326.00	
	Dengan Komorbid	Mean	226.2381	21.01540
		Median	211.0000	
		Std. Deviation	96.30468	
		Minimum	20.00	
		Maximum	469.00	
D_dimer	Tanpa Komorbid	Mean	22.6822	9.51810
		Median	8.1900	
		Std. Deviation	28.55429	
		Minimum	1.68	
		Maximum	82.50	
	Dengan Komorbid	Mean	77.1029	57.17933
		Median	10.0000	
		Std. Deviation	262.02860	
		Minimum	.82	
		Maximum	1214.52	
IL6	Tanpa Komorbid	Mean	422.1289	194.18464
		Median	147.8000	
		Std. Deviation	582.55392	
		Minimum	31.24	
		Maximum	1840.00	
	Dengan Komorbid	Mean	1030.9495	353.82256
		Median	144.6000	
		Std. Deviation	1621.41868	
		Minimum	13.19	
		Maximum	5000.00	

Lampiran 10 Hubungan Jenis Kelamin Terhadap Derajat Klinis Covid-19

**Jenis\_Kelamin \* Derajat\_Covid19 Crosstabulation**

			Derajat_Covid19		Total
			non Severe	Severe	
Jenis_Kelamin	Laki_laki	Count	4	21	25
		% of Total	10.3%	53.8%	64.1%
	Perempuan	Count	2	12	14
		% of Total	5.1%	30.8%	35.9%
Total		Count	6	33	39
		% of Total	15.4%	84.6%	100.0%

**Chi-Square Tests**

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.020 <sup>a</sup>	1	.887		
Continuity Correction <sup>b</sup>	.000	1	1.000		
Likelihood Ratio	.020	1	.886		
Fisher's Exact Test				1.000	.635
Linear-by-Linear Association	.020	1	.888		
N of Valid Cases	39				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 2.15.

b. Computed only for a 2x2 table

Lampiran 11 Hubungan Jenis Kelamin Terhadap Riwayat Komorbid Pada Pasien Covid-19

**Jenis\_Kelamin \* Komorbid Crosstabulation**

			Komorbid		Total
			Tanpa Komorbid	Dengan Komorbid	
Jenis_Kelamin	Laki_laki	Count	7	18	25
		% of Total	17.9%	46.2%	64.1%
	Perempuan	Count	4	10	14
		% of Total	10.3%	25.6%	35.9%
Total		Count	11	28	39
		% of Total	28.2%	71.8%	100.0%



### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.001 <sup>a</sup>	1	.970		
Continuity Correction <sup>b</sup>	.000	1	1.000		
Likelihood Ratio	.001	1	.970		
Fisher's Exact Test				1.000	.624
Linear-by-Linear Association	.001	1	.970		
N of Valid Cases	39				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 3.95.

b. Computed only for a 2x2 table

Lampiran 12 Hubungan Umur Terhadap Derajat Klinis Covid-19

### Umur \* Derajat\_Covid19 Crosstabulation

		Derajat_Covid19			
		non Severe	Severe	Total	
Umur	< 60 tahun	Count	3	11	14
		% of Total	7.7%	28.2%	35.9%
	≥ 60 tahun	Count	3	22	25
		% of Total	7.7%	56.4%	64.1%
Total		Count	6	33	39
		% of Total	15.4%	84.6%	100.0%

### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.613 <sup>a</sup>	1	.434		
Continuity Correction <sup>b</sup>	.103	1	.749		
Likelihood Ratio	.593	1	.441		
Fisher's Exact Test				.647	.365
Linear-by-Linear Association	.597	1	.440		
N of Valid Cases	39				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 2.15.

b. Computed only for a 2x2 table

Lampiran 13 Hubungan Umur Terhadap Riwayat Komorbid Pada Pasien Covid-19

**Umur \* Komorbid Crosstabulation**

			Komorbid		Total
			Tanpa Komorbid	Dengan Komorbid	
Umur	< 60 tahun	Count	5	9	14
		% of Total	12.8%	23.1%	35.9%
	≥ 60 tahun	Count	6	19	25
		% of Total	15.4%	48.7%	64.1%
Total		Count	11	28	39
		% of Total	28.2%	71.8%	100.0%

**Chi-Square Tests**

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.608 <sup>a</sup>	1	.435		
Continuity Correction <sup>b</sup>	.167	1	.683		
Likelihood Ratio	.597	1	.440		
Fisher's Exact Test				.478	.337
Linear-by-Linear Association	.593	1	.441		
N of Valid Cases	39				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 3.95.

b. Computed only for a 2x2 table

Lampiran 14 Hubungan Jumlah Trombosit Terhadap Derajat Klinis Covid-19

**Kat\_Trombosit \* Derajat\_Covid19 Crosstabulation**

			Derajat_Covid19		Total
			non Severe	Severe	
Kat_Trombosit	Rendah	Count	3	7	10
		% of Total	7.9%	18.4%	26.3%
	Normal	Count	3	24	27
		% of Total	7.9%	63.2%	71.1%
	Tinggi	Count	0	1	1
		% of Total	0.0%	2.6%	2.6%
Total		Count	6	32	38
		% of Total	15.8%	84.2%	100.0%

### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	2.151 <sup>a</sup>	2	.341
Likelihood Ratio	2.094	2	.351
Linear-by-Linear Association	2.059	1	.151
N of Valid Cases	38		

a. 4 cells (66.7%) have expected count less than 5. The minimum expected count is .16.

Lampiran 15 Hubungan Jumlah Trombosit Terhadap Riwayat Komorbid Pada Pasien Covid-19

### Kat\_Trombosit \* Komorbid Crosstabulation

		Komorbid		Total	
		Tanpa Komorbid	Dengan Komorbid		
Kat_Trombosit	Rendah	Count	4	6	10
		% of Total	10.5%	15.8%	26.3%
	Normal	Count	7	20	27
		% of Total	18.4%	52.6%	71.1%
	Tinggi	Count	0	1	1
		% of Total	0.0%	2.6%	2.6%
Total		Count	11	27	38
		% of Total	28.9%	71.1%	100.0%

### Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	1.121 <sup>a</sup>	2	.571
Likelihood Ratio	1.364	2	.506
Linear-by-Linear Association	1.038	1	.308
N of Valid Cases	38		

a. 3 cells (50.0%) have expected count less than 5. The minimum expected count is .29.

## Lampiran 16 Hubungan PT Terhadap Derajat Klinis Covid-19

**Kat\_PT \* Derajat\_Covid19 Crosstabulation**

		Derajat_Covid19		Total	
		non Severe	Severe		
Kat_PT	Normal	Count	3	13	16
		% of Total	10.0%	43.3%	53.3%
	Tinggi	Count	2	12	14
		% of Total	6.7%	40.0%	46.7%
Total		Count	5	25	30
		% of Total	16.7%	83.3%	100.0%

**Chi-Square Tests**

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.107 <sup>a</sup>	1	.743		
Continuity Correction <sup>b</sup>	.000	1	1.000		
Likelihood Ratio	.108	1	.743		
Fisher's Exact Test				1.000	.567
Linear-by-Linear Association	.104	1	.748		
N of Valid Cases	30				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 2.33.

b. Computed only for a 2x2 table

## Lampiran 17 Hubungan PT Terhadap Riwayat Komorbid Pada Pasien Covid-19

**Kat\_PT \* Komorbid Crosstabulation**

		Komorbid		Total	
		Tanpa Komorbid	Dengan Komorbid		
Kat_PT	Normal	Count	6	10	16
		% of Total	20.0%	33.3%	53.3%
	Tinggi	Count	3	11	14
		% of Total	10.0%	36.7%	46.7%
Total		Count	9	21	30
		% of Total	30.0%	70.0%	100.0%

### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1- sided)
Pearson Chi-Square	.918 <sup>a</sup>	1	.338		
Continuity Correction <sup>b</sup>	.313	1	.576		
Likelihood Ratio	.934	1	.334		
Fisher's Exact Test				.440	.290
Linear-by-Linear Association	.888	1	.346		
N of Valid Cases	30				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 4.20.

b. Computed only for a 2x2 table

Lampiran 18 Hubungan APTT Terhadap Derajat Klinis Covid-19

### Kat\_APTT \* Derajat\_Covid19 Crosstabulation

		Derajat_Covid19		Total	
		non Severe	Severe		
Kat_APTT	Rendah	Count	0	4	4
		% of Total	0.0%	13.3%	13.3%
	Normal	Count	2	9	11
		% of Total	6.7%	30.0%	36.7%
	Tinggi	Count	3	12	15
		% of Total	10.0%	40.0%	50.0%
Total	Count	5	25	30	
	% of Total	16.7%	83.3%	100.0%	

### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	.938 <sup>a</sup>	2	.626
Likelihood Ratio	1.591	2	.451
Linear-by-Linear Association	.633	1	.426
N of Valid Cases	30		

a. 4 cells (66.7%) have expected count less than 5. The minimum expected count is .67.

Lampiran 19 Hubungan APTT Terhadap Riwayat Komorbid Pada Pasien Covid-19

**Kat\_APTT \* Komorbid Crosstabulation**

		Komorbid		Total	
		Tanpa Komorbid	Dengan Komorbid		
Kat_APTT	Rendah	Count	2	2	4
		% of Total	6.7%	6.7%	13.3%
	Normal	Count	4	7	11
		% of Total	13.3%	23.3%	36.7%
	Tinggi	Count	3	12	15
		% of Total	10.0%	40.0%	50.0%
Total	Count	9	21	30	
	% of Total	30.0%	70.0%	100.0%	

**Chi-Square Tests**

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	1.688 <sup>a</sup>	2	.430
Likelihood Ratio	1.674	2	.433
Linear-by-Linear Association	1.627	1	.202
N of Valid Cases	30		

a. 4 cells (66.7%) have expected count less than 5. The minimum expected count is 1.20.

Lampiran 20 Hubungan Derajat Klinis Covid-19 Terhadap Riwayat Komorbid Pasien Covid-19 Terkait D-dimer

**Komorbid \* Derajat\_Covid19 \* Kat\_DDimer Crosstabulation**

Kat_DDimer			Derajat_Covid19		Total	
			non Severe	Severe		
Meningkat	Komorbid	Tanpa	Count	3	8	11
		Komorbid	% of Total	7.7%	20.5%	28.2%
	Dengan	Komorbid	Count	3	25	28
		Komorbid	% of Total	7.7%	64.1%	71.8%
	Total	Komorbid	Count	6	33	39
		Komorbid	% of Total	15.4%	84.6%	100.0%
Total	Komorbid	Tanpa	Count	3	8	11
		Komorbid	% of Total	7.7%	20.5%	28.2%
	Dengan	Komorbid	Count	3	25	28
		Komorbid	% of Total	7.7%	64.1%	71.8%
	Total	Komorbid	Count	6	33	39
		Komorbid	% of Total	15.4%	84.6%	100.0%

### Chi-Square Tests

Kat_DDimer		Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Meningkat	Pearson Chi-Square	1.663 <sup>a</sup>	1	.197		
	Continuity Correction <sup>b</sup>	.635	1	.426		
	Likelihood Ratio	1.528	1	.216		
	Fisher's Exact Test				.323	.208
	Linear-by-Linear Association	1.621	1	.203		
	N of Valid Cases	39				
Total	Pearson Chi-Square	1.663 <sup>a</sup>	1	.197		
	Continuity Correction <sup>b</sup>	.635	1	.426		
	Likelihood Ratio	1.528	1	.216		
	Fisher's Exact Test				.323	.208
	Linear-by-Linear Association	1.621	1	.203		
	N of Valid Cases	39				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.69.

b. Computed only for a 2x2 table

Lampiran 21 Hubungan Derajat Klinis Covid-19 Terhadap Riwayat Komorbid Pasien Covid-19 Terkait IL-6

### Komorbid \* Derajat\_Covid19 \* Kat\_IL6 Crosstabulation

Kat_IL6				Derajat_Covid19		Total
				non Severe	Severe	
Meningkat	Komorbid	Tanpa	Count	3	8	11
		Komorbid	% of Total	7.7%	20.5%	28.2%
	Dengan	Komorbid	Count	3	25	28
		Komorbid	% of Total	7.7%	64.1%	71.8%
	Total	Komorbid	Count	6	33	39
		Komorbid	% of Total	15.4%	84.6%	100.0%
Total	Komorbid	Tanpa	Count	3	8	11
		Komorbid	% of Total	7.7%	20.5%	28.2%
	Dengan	Komorbid	Count	3	25	28
		Komorbid	% of Total	7.7%	64.1%	71.8%
	Total	Komorbid	Count	6	33	39
		Komorbid	% of Total	15.4%	84.6%	100.0%

### Chi-Square Tests

Kat_IL6		Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Meningkat	Pearson Chi-Square	1.663 <sup>a</sup>	1	.197		
	Continuity Correction <sup>b</sup>	.635	1	.426		
	Likelihood Ratio	1.528	1	.216		
	Fisher's Exact Test				.323	.208
	Linear-by-Linear Association	1.621	1	.203		
	N of Valid Cases	39				
Total	Pearson Chi-Square	1.663 <sup>a</sup>	1	.197		
	Continuity Correction <sup>b</sup>	.635	1	.426		
	Likelihood Ratio	1.528	1	.216		
	Fisher's Exact Test				.323	.208
	Linear-by-Linear Association	1.621	1	.203		
	N of Valid Cases	39				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.69.

b. Computed only for a 2x2 table